LIKMEZ Drug Patent Profile
✉ Email this page to a colleague
When do Likmez patents expire, and what generic alternatives are available?
Likmez is a drug marketed by Saptalis Pharms and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
The generic ingredient in LIKMEZ is metronidazole. There is one drug master file entry for this compound. Sixty-seven suppliers are listed for this compound. Additional details are available on the metronidazole profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Likmez
A generic version of LIKMEZ was approved as metronidazole by TEVA PHARMS USA on November 6th, 1984.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for LIKMEZ?
- What are the global sales for LIKMEZ?
- What is Average Wholesale Price for LIKMEZ?
Summary for LIKMEZ
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Clinical Trials: | 1 |
| Drug Prices: | Drug price information for LIKMEZ |
| What excipients (inactive ingredients) are in LIKMEZ? | LIKMEZ excipients list |
| DailyMed Link: | LIKMEZ at DailyMed |
Recent Clinical Trials for LIKMEZ
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| CBCC Global Research | PHASE2 |
| Saptalis Pharmaceuticals LLC | PHASE2 |
Pharmacology for LIKMEZ
| Drug Class | Nitroimidazole Antimicrobial |
Paragraph IV (Patent) Challenges for LIKMEZ
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| LIKMEZ | Oral Suspension | metronidazole | 500 mg/5 mL | 216755 | 1 | 2025-11-13 |
US Patents and Regulatory Information for LIKMEZ
LIKMEZ is protected by four US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Saptalis Pharms | LIKMEZ | metronidazole | SUSPENSION;ORAL | 216755-001 | Sep 22, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Saptalis Pharms | LIKMEZ | metronidazole | SUSPENSION;ORAL | 216755-001 | Sep 22, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for LIKMEZ
See the table below for patents covering LIKMEZ around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Brazil | 112020014376 | ⤷ Start Trial | |
| Canada | 3087789 | ⤷ Start Trial | |
| European Patent Office | 3768321 | ⤷ Start Trial | |
| Mexico | 2020007494 | ⤷ Start Trial | |
| World Intellectual Property Organization (WIPO) | 2019140516 | ⤷ Start Trial | |
| Canada | 3087789 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for LIKMEZ
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0328535 | 96C0021 | Belgium | ⤷ Start Trial | PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch